Page 2 - Deals Andm Amp A News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Deals andm amp a. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Deals Andm Amp A Today - Breaking & Trending Today

China's investigator trials accelerate competitive CAR T development

China’s CAR T market is expected to grow from $72 million in 2022 to $342 million over the next decade. There are currently more than 400 CAR T therapies in the pipeline in China, and most of these are being developed by specialized Chinese biotechs. Research by Clarivate plc, BioWorld’s parent company, indicates that a notable proportion of CAR T-cell therapies in late-phase development in China are being developed through strategic partnerships and joint ventures between multinational corporations and domestic companies, including Johnson & Johnson and Nanjing Legend Biotech Corp., Juno Therapeutics Inc. and Wuxi Apptec Co. Ltd., and CASI Pharmaceuticals Inc. and Juventas Cell Therapy Ltd. ....

Wuxi Apptec Co , Juventas Cell Therapy Ltd , Pharmaceuticals Inc , Juno Therapeutics Inc , Legend Biotech Corp , Nanjing Legend Biotech Corp , Juno Therapeutics , Wuxi Apptec , Juventas Cell Therapy , Johnson Amp , Nanjing Legend Biotech Co , Juno Therapeutics Inc , Wuxi Apptec Co Ltd , Casi Pharmaceuticals Inc , Juventas Cell Therapy Ltd , Asia Pacific , Car T , Analysis And Data Insight , Deals Andm Amp A ,

Bruker unties Nanostring bankruptcy knot with $393M winning bid

Bruker Corp. shows no sign of slowing its buying binge, picking up Nanostring Technologies Inc. for $392.6 million in cash plus the assumption of certain liabilities in its seventh deal so far this year.
Nanostring entered bankruptcy in February and received a “stalking horse” bid of $220 million from private equity fund Patient Square Capital in March. Bruker won the competitive auction for Nanostring’s assets, besting the Patient Square bid by 78%. The deal is expected to close in early May. ....

Bruker Corp , Nanostring Technologies Inc , Nanostring Technologies , Patient Square Capital , Patient Square , Bioworld Medtech , Bruker Corp , Nanostring Technologies Inc , Elistechgroup Sas , Chemspeed Technologies Ag , 10x Genomics Inc , Deals Andm Amp A ,

Vertex buying Alpine for $4.9B for phase III-ready IgAN asset

Vertex Pharmaceuticals Inc. is acquiring Alpine Immune Sciences Inc. for $4.9 billion in cash to gain Alpine’s lead product, phase III-ready povetacicept, which demonstrates best-in-class potential in patients with immunoglobulin A nephropathy (IgAN). ....

Reshma Kewalramani , Vertex Pharmaceuticals Inc , Alpine Immune Sciences Inc , Vertex Pharmaceuticals , Alpine Immune Sciences , Alpine Immune Sciences Inc , Vertex Pharmaceuticals Inc , Kidney Disease , Immunoglobulina Nephropathy , Immunoglobulin A , Deals Andm Amp A , Endocrine Metabolic , Genitourinary Sexual Function ,

J&J paces interventional cardio market with $13B Shockwave buy

Med-tech powerhouse Johnson & Johnson made a bold bid to bolster its interventional cardiology holdings with the news on April 5 that it is acquiring Shockwave Medical Inc. for approximately $13.1 billion including cash acquired. The $335 per share cash price represents a more than 5% premium to Shockwave’s (Nasdaq: SWAV) April 4 closing price and a more than 17% premium to the stock price prior to the Wall Street Journal report last week about the rumoured deal. ....

Shockwave Medical Inc , Shockwave Medical , Wall Street Journal , Deals Andm Amp A , Bioworld Medtech , Johnson Amp , Shockwave Medical Inc , Coronary Artery Disease , Peripheral Artery Disease , Intravascular Lithotripsy , Laminar Inc , Abiomed Inc ,

In first major M&A, Genmab adding Profoundbio for $1.8B

Investors might not have been overly excited, but Genmab A/S executives enthused about the “complementarity” of its proposed acquisition of antibody-drug conjugate (ADC) specialist Profoundbio Inc. for $1.8 billion in cash. The deal, expected to close in the first half of 2024, marks the biggest by far for the Copenhagen, Denmark-based biopharma and the latest transaction for the red hot ADC space. ....

Profoundbio Inc , Genmaba S , Profoundbio Inc , Deals Andm Amp A , Antibody Drug Conjugate , Rinatabart Sesutecan , Rina S , Hydrophilic Linker , Ovarian Cancer ,